Slayback Pharmaceuticals
About Slayback Pharmaceuticals
Slayback Pharmaceuticals is a company based in West Windsor Township (United States) founded in 2011 was acquired by Azurity Pharmaceuticals in September 2023.. Slayback Pharmaceuticals has raised $110 million across 2 funding rounds from investors including KKR, Everstone Capital and Azurity Pharmaceuticals. Slayback Pharmaceuticals offers products and services including XIFYRM and FIRVANQ.
- Headquarter West Windsor Township, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Azurity Pharmaceuticals, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$110 M (USD)
in 2 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 06, 2020
-
Investors
KKR
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Azurity Pharmaceuticals
(Sep 01, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Slayback Pharmaceuticals
Slayback Pharmaceuticals offers a comprehensive portfolio of products and services, including XIFYRM and FIRVANQ. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
XIFYRM is utilized for the management of moderate-to-severe pain in adults as an IV non-steroidal anti-inflammatory drug.
FIRVANQ is employed as an anti-infective treatment in various therapeutic contexts.
Unlock access to complete
Unlock access to complete
Funding Insights of Slayback Pharmaceuticals
Slayback Pharmaceuticals has successfully raised a total of $110M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $50.0M
-
First Round
First Round
(01 Dec 2016)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series B - Slayback Pharmaceuticals | Valuation | Everstone Capital | |
| Dec, 2016 | Amount | Series A - Slayback Pharmaceuticals | Valuation | KKR |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Slayback Pharmaceuticals
Slayback Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include KKR, Everstone Capital and Azurity Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in mid-market businesses linked to India and Southeast Asia.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Generic drugs are manufactured by Azurity Pharmaceuticals in the US.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Slayback Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Slayback Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Slayback Pharmaceuticals Comparisons
Competitors of Slayback Pharmaceuticals
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Slayback Pharmaceuticals
When was Slayback Pharmaceuticals founded?
Slayback Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Where is Slayback Pharmaceuticals located?
Slayback Pharmaceuticals is headquartered in West Windsor Township, United States. It is registered at West Windsor Township, New Jersey, United States.
Is Slayback Pharmaceuticals a funded company?
Slayback Pharmaceuticals is a funded company, having raised a total of $110M across 2 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on Dec 01, 2016.
What does Slayback Pharmaceuticals do?
Slayback Pharmaceuticals was founded in 2011 and is based in West Windsor Township, United States. Operations center on the pharmaceutical sector, producing specialty generics through complex formulations including sterile injectables, emulsions, suspensions, microspheres, topical products, foams, aerosols, controlled substances with advanced delivery, and high-bioavailability oral products. FDA approval has been secured for a generic acyclovir ointment targeting herpes infections in specific patient groups.
What products or services does Slayback Pharmaceuticals offer?
Slayback Pharmaceuticals offers XIFYRM and FIRVANQ.
Who are Slayback Pharmaceuticals's investors?
Slayback Pharmaceuticals has 3 investors. Key investors include KKR, Everstone Capital, and Azurity Pharmaceuticals.